The National Institute for Innovation in Manufacturing Biopharmaceuticals ( NIIMBL ) has awarded funding to Johns Hopkins University to assess the capabilities of long-read next-generation sequencing (NGS) methods for characterizing and controlling the quality of adeno-associated viral vectors (AAV vectors). The award stems from NIIMBL’s Viral...
Today, Commissioners from the National Security Commission on Emerging Biotechnology (NSCEB), along with Senator Chris Coons (D-DE) and Representative Sarah McBride (D-DE), visited the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) to see firsthand how government and industry partnerships drive excellence in...
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce student applications for the 2025 NIIMBL eXperience are now open. Students can apply to one of seven unique programs hosted by NIIMBL members across the country:
Albany College of Pharmacy and Health Sciences (ACPHS) (New York)...
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) has published “ Vaccine process technology—a decade of progress ” in Biotechnology and Bioengineering . The paper serves as an update to a 2012 review titled “ Vaccine process technology ” authored by NIIMBL Executive Director Barry Buckland and explores...
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) officially launches the Viral Vectors NIIMBL-led Program focused on developing and making broadly available robust, economically viable, shared manufacturing process and analytical platforms for Adeno-Associated Virus (AAV) gene therapy vectors. NIIMBL has committed...
